ArticleReproductive sciences (Thousand Oaks, Calif.)2026
NMN Can Restore Ovarian Reserve in Aged Mice by Upregulating NAD
Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Female reproductive aging is linked to declining nicotinamide adenine dinucleotide (NAD+) levels and mitochondrial dysfunction. While nicotinamide mononucleotide (NMN) supplementation can counteract this, its mechanisms remain unclear. This study investigated NMN’s effects in aged female mice administered 200, 500, or 1000 mg/kg/day NMN for 10 days, compared to aged and young controls. An optimal dose of 500 mg/kg/day was identified for restoring ovarian follicle reserve. This treatment significantly increased ovarian NAD+ and ATP, reduced oocyte oxidative stress (ROS) and apoptosis, and rejuvenated mitochondrial function. Mechanistically, NMN activated the NAD+/SIRT1/PGC-1α signaling pathway and upregulated the mitochondrial biogenesis protein TOMM20. In vitro, supplementing culture medium with 1 µM NMN optimally enhanced the developmental potential of aged oocytes. Both in vivo and in vitro interventions showed dose-dependent efficacy. We conclude that NMN mitigates ovarian aging by enhancing mitochondrial function via the NAD+/SIRT1/PGC-1α-TOMM20 axis.
Indexed as
Identifiers
41951910What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.